GALT

Galectin Therapeutics Inc. (NASDAQ:GALT) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Norcross, Georgia. Originally incorporated as Pro-Pharmaceuticals, Inc., the company changed its name to Galectin Therapeutics in May 2011 to reflect its focus on developing therapies that target galectin proteins. The company went public in 2002 and has spent over two decades developing treatments for fibrotic diseases, cancer, and other conditions through its specialized approach of inhibiting galectin-3, a protein involved in inflammation and tissue scarring processes.